Oncology Venture gets option to in-license European rights to IXEMPRA

By Nikita Chaurasia  Date: 2019-04-05

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Canada limits 5G around airports over aircraft interference concerns

Canada limits 5G around airports over aircraft interference concerns

By Nikita Chaurasia

Much to the surprise of the telecom industry, the Department of Innovation, Science, and Economic Development (ISED) of Canada has reportedly decided to limit some 5G services that could possibly interfere with radio altimeters, which are crucial com...

U.S. planning to invest billions to expand COVID-19 vaccine production

U.S. planning to invest billions to expand COVID-19 vaccine production

By Nikita Chaurasia

The United States is reportedly planning to make substantial investments to improve its COVID-19 vaccine manufacturing capacity. The country intends to produce at least a billion doses by the second half of 2022. This decision is driven by the huge ...

Peloton sues rival firms iFit and Echelon for patent infringement

Peloton sues rival firms iFit and Echelon for patent infringement

By Nikita Chaurasia

U.S.-based exercise equipment and media company Peloton Interactive Inc. has reportedly filed lawsuits against its rivals Echelon Fitness and iFit, claiming that they violated patents related to its on-demand classes. Peloton stated that Echelon and...

Apple’s digital ID card plan could be funded through states, taxpayers

Apple’s digital ID card plan could be funded through states, taxpayers

By Nikita Chaurasia

Apple is reportedly working on allowing users in participating states to digitally store their state IDs  or driver’s licenses on their iPhone wallet. However, the multibillion-dollar company will partially rely on the respective states &m...

South Korea demonstrates systems for urban air mobility management

South Korea demonstrates systems for urban air mobility management

By Nikita Chaurasia

South Korea has reportedly tested methods for operating urban air mobility (UAM) vehicles, which it aims to use for taxis that will fly between downtown Seoul and major airports as early as 2025. In 2020, South Korea had announced its plan to launch...